CellSeed Inc.
7776.TJPXHealthcareBiotechnology
Latest quote
¥232
−¥1.00 · -0.43%
7776.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteCellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Setsuko Hashimoto
- Listed since
- Mar 16, 2010
- Employees
- 36
Market position
Day range
Current ¥232
52-week range
Current ¥232
- Open
- ¥233
- Previous close
- ¥233
- Volume
- 162.7K
- 0.68× average
- Average volume
- 238.98K
- Average daily volume
- Market cap
- 9.02B JPY
- Beta
- 1.2
- Market reference 1
- 50-day average
- ¥220.48
- +5.22% above average
- 200-day average
- ¥277.42
- -16.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 7.8B JPY
- P/E (TTM)
- -8.01×
- P/B (TTM)
- 5.1×
- P/S (TTM)
- 133.61×
- EV / EBITDA
- -7.46×
- Earnings yield
- -12.29%
- Free cash flow yield
- -11.30%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 59.03%
- Operating margin
- -1472.32%
- Net margin
- -1575.63%
- Return on equity
- -87.05%
- Return on assets
- -66.68%
- Return on invested capital
- -72.89%
Financial health
- Debt / equity
- 0.07×
- Current ratio
- 6.13×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 83.68M JPY | 193.28M JPY | 190.13M JPY | 126.43M JPY | 161.67M JPY |
| Cost of goods sold | 40.93M JPY | 83.17M JPY | 82.98M JPY | 65.41M JPY | 77.64M JPY |
| Gross profit | 42.75M JPY | 110.11M JPY | 107.16M JPY | 61.02M JPY | 84.04M JPY |
| Research and development | 720.05M JPY | 573.32M JPY | 456.41M JPY | 444.76M JPY | 541.24M JPY |
| Selling, general, and administrative | 368.83M JPY | 383.17M JPY | 348.52M JPY | 359.48M JPY | 387M JPY |
| Operating expenses | 1.09B JPY | 956.49M JPY | 804.93M JPY | 804.23M JPY | 948.15M JPY |
| Interest income | 2.76M JPY | 232K JPY | 13K JPY | 10K JPY | 13K JPY |
| Interest expense | 1.95M JPY | 2.06M JPY | 1.13M JPY | 835K JPY | 911K JPY |
| Depreciation and amortization | — | 1K JPY | 7.94M JPY | 7.89M JPY | 2.49M JPY |
| Operating income | −1.05B JPY | −846.38M JPY | −697.78M JPY | −743.22M JPY | −864.11M JPY |
| Net income | −1.1B JPY | −859.84M JPY | −846.53M JPY | −759.68M JPY | −912.87M JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -8.69
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
7776.T peers
Continue in GoAI
Research 7776.Tresearch.disclaimer